Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.1MCash on Hand
1.1mo Cash Runway
Follow TVGN by emailGet an email when TVGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TVGN, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Financing Tevogen registered for resale up to 1,029,126 common shares held by a selling stockholder, issued in November 2026 as payment of loan principal and accrued interest under a loan agreement amended October 27, 2026. The company will receive no proceeds from the resale. Shares closed at $6.00 on November 13, 2026. Form S-3 · SEC filing
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 4, 2026 ·
Leadership Director Susan Podlogar resigned effective immediately on November 2, 2026. The board reduced its size from six to five directors and appointed Lindee Goh to the Audit Committee. Form 8-K · SEC filing
Nov 3, 2026 ·
Financing Tevogen amended its $36.0 million loan facility with The Patel Family, LLP, extending the borrowing period to May 31, 2029, fixing the share price at $7.40, and repaid the $7.4 million principal and $177,880 interest in 1,000,000 and 23,733 shares on November 2, 2026. Form 8-K · SEC filing
Sep 30, 2026 ·
Listing Tevogen received Nasdaq notice on September 29, 2026 that it regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on the Nasdaq Global Market, closing the matter. This follows a September 9, 2026 notice on publicly held shares requirements. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Leadership Tevogen granted CEO Ryan Saadi 8,000,000 restricted shares and CFO Kirti Desai 750,000 restricted shares on September 14, 2026. Vesting requires $1.0 billion in aggregate revenue by September 30, 2031, and the executives may vote the shares before vesting. Form 8-K · SEC filing
Sep 10, 2026 ·
Listing Nasdaq notified Tevogen it regained compliance with the $15 million minimum market value of publicly held shares requirement for continued listing on the Nasdaq Global Market, closing the matter. Form 8-K · SEC filing
Aug 26, 2026 ·
Shareholder vote Stockholders approved a 100,000,000-share increase to the 2024 Omnibus Incentive Plan and an amendment allowing stockholder action by written consent, and re-elected directors Keow Lin Goh and Victor Sordillo as Class II directors. KPMG LLP was ratified as auditor for 2026. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TVGN holds $1.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.9M/quarter from operations,
an estimated runway of 1.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 1 months +40
ATM program on file since Jul 2025 +15
Shelf registration (S-3, Jun 2025) +10
Raised after last reported balance sheet (Nov 2026) -10
Share count 68,678,743 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TVGN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.